ASAP3 regulates microvilli structure in parietal cells and presents intervention target for gastric acidity

作者：Qian, Jin; Li, Yueyuan; Yao, Han; Tian, Haiying; Wang, Huanbin; Ai, Luoyan; Xie, Yuanhong; Bao, Yujie; Liang, Lunxi; Hu, Ye; Zhang, Yao; Wang, Jilin; Li, Chushu; Tang, Jiayin; Chen, Yingxuan; Xu, Jie^*; Fang, Jing-Yuan^*

来源：Signal Transduction and Targeted Therapy, 2017, 2(1): e17003.

DOI：10.1038/sigtrans.2017.3

• GASTROESOPHAGEAL-REFLUX DISEASE
• COMPLEX
• EZRIN
• PHOSPHORYLATION
• MECHANISM
• CANCER
• RISK

Gastric acidity-associated disorders such as peptic ulcer and reflux diseases are widespread, and the reported resistance and side effects of currently used medicines suggest an urgent requirement for alternative therapeutic approaches. Here we demonstrate a critical role of ASAP3 in regulating the microvilli structure of parietal cells in vivo, and reveal the feasibility of controlling gastric acidity by targeting ASAP3. Conditional knockout of ASAP3 in mice caused elongation and stacking of microvilli in parietal cells, and substantially decreased gastric acid secretion. These were associated with active assembly of F-actin caused by a higher level of GTP-bound Arf6 GTPase. Consistently, a small molecular compound QS11 inhibited ASAP3 function and significantly reduced gastric acidity in vivo. Of note, the expression of ASAP3 was positively correlated with gastric acid secretion in 90 human cases, and high expression of ASAP3 was associated with reflux disease and peptic ulcer. These results reveal for the first time that ASAP3 regulates the microvilli structures in parietal cells. Our data also suggest ASAP3 as a feasible and drugable therapeutic target for gastric acidity-associated diseases.

• 出版日期2017
• 单位上海交通大学